Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | FABP7 | O15540 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14276798 | 0.88 | TSHR (0.60) | TSHRFABP7PPARGFABP5CYP1A2 | |
| SCHEMBL5122894 | 0.88 | TSHR (0.60) | TSHRFABP7PPARGFABP5CYP1A2 | |
| SCHEMBL12694396 | 0.87 | HDAC4 (0.61) | HDAC4TSHRFABP7PPARGFABP5 | |
| SCHEMBL12694395 | 0.86 | TSHR (0.49) | HDAC4TSHRFABP7PPARGFABP5 | |
| SCHEMBL15786645 | 0.86 | TSHR (0.49) | HDAC4TSHRFABP7PPARGFABP5 | |
| SCHEMBL15783747 | 0.85 | FABP7 (0.60) | HDAC4TSHRFABP7PPARGFABP5 | |
| SCHEMBL18462855 | 0.85 | GAA (0.63) | TSHRFABP7PPARGFABP5CYP1A2 | |
| SCHEMBL17366557 | 0.85 | GAA (0.63) | TSHRFABP7PPARGFABP5CYP1A2 | |
| SCHEMBL18418086 | 0.85 | GAA (0.63) | TSHRFABP7PPARGFABP5CYP1A2 | |
| SCHEMBL15768954 | 0.84 | HDAC4 (0.58) | HDAC4TSHRFABP7PPARGFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885TSHR 4604/4885FABP7 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.